

Support for Policies to Protect Seniors from Government Rationing and Lower Drug Prices with Competition





## **KEY TAKEAWAYS**

- Policies to protect seniors from government rationing and to improve competition to lower drug prices draw strong support.
- The support is on par with Biden's Medicare price negotiation policies in the Inflation Reduction Act and significantly higher than proposals to base Medicare prices on what they pay in Europe, where access to many newer medicines are limited to price controls.
- The findings show that advocates of free markets in prescription drugs have solutions to lower drug prices that compare favorably with government-centric proposals.



# **Strong Support for Policies to Protect Seniors from Government Rationing and Improve Competition**

SUPPORT AS STRONG AS MEDICARE PRICE SETTING AND MUCH HIGHER THAN FOREIGN PRICE BENCHMARKS


		0 1 4	0 1 .	0, 1		% Su	pport			New Mai	New Maj	New Mai	Left
"Do you support or oppose the following policy proposals?"	Strongly Support	Somewhat Support	Somewhat Oppose	Strongly Oppose	Don't Know	All	Rep	Ind	Dem	(All)	Und	Dem	Min
Require Medicare to cover all drugs approved by the FDA		55		30	<b>62</b> 7	85	83	86	86	84	80	89	87
Require pharmacies to transfer prescriptions if patient requests		54		31	<mark>62</mark> 8	84	86	82	84	84	73	86	85
Close legal loopholes that delay and discourage cheaper generics		52		28	7 5 8	81	82	80	79	81	78	86	80
Expand Medicare's ability to negotiate directly with drug manufacturers		51		36	<b>42</b> 7	87	89	83	88	85	77	91	91
Require savings found in Medicare be kept in Medicare		48		35	<mark>62</mark> 9	83	85	80	82	82	74	84	84
Require all medicines over 13 years old be priced as generics		48		34	729	82	82	82	81	81	76	90	83
Require drug middlemen to pass savings directly to patients		47		32 8	<b>3</b> 11	78	77	78	80	78	69	87	80
Prioritize approval of lower cost generic drugs		44		40	<mark>6</mark> 29	83	81	84	85	82	75	90	86
Allow insurers to jointly negotiate for drug lower prices		40	4	1	<b><u>6</u> 3</b> 10	81	85	76	80	82	72	85	79
Modernize the FDA to get more medicines to the market faster		38	40	9	<b>3</b> 10	78	79	76	79	79	73	85	77
Switch some prescription drugs to over the counter		36	42	1	1 2 10	78	78	75	79	78	73	79	77
Penalize countries that pay less than market value for U.Smade drugs	28		31	12 5	23	59	69	50	56	63	47	62	49
Allow pharmacies to substitute biosimilars for brand name biologics	27		38	11 5	19	65	66	63	67	65	64	67	65
Base price of drugs in the U.S. on what they pay in Europe	24	28	13	6	29	52	47	50	58	50	46	58	58
	1	I I I	1	I I	I							<b>→</b> 2000	


6 30% 40% 50% 60% 70% 80% 90% 100%





## **Medicare Must Cover FDA Approved Drugs**









## **Medicare Must Cover FDA Approved Drugs**

### NEW MAJORITY CROSSTABS






## **Allow Patient Request Prescription Transfers**






## **Allow Patient Request Prescription Transfers**

### NEW MAJORITY CROSSTABS






## **Close Loopholes that Delay Competition**





## **Close Loopholes that Delay Competition**

### NEW MAJORITY CROSSTABS




\*New Majority voters are determined through a screener survey of statements, asking respondents to rank their agreement on a 0 to 10 scale, as well as the intensity of their approval of the president and party preference on the generic ballot.

rica

ority pro


## **Expand Medicare Negotiation w/ Drug Manufacturers**






## **Expand Medicare Negotiation w/ Drug Manufacturers**

### NEW MAJORITY CROSSTABS






## **Medicare Savings Stay In Medicare**






## **Medicare Savings Stay In Medicare**

### NEW MAJORITY CROSSTABS






### **Reprice Medication as Generics**






### **Reprice Medication as Generics**

### NEW MAJORITY CROSSTABS






### **Middlemen Pass Savings to Patients**





### **Middlemen Pass Savings to Patients**

### NEW MAJORITY CROSSTABS




\*New Majority voters are determined through a screener survey of statements, asking respondents to rank their agreement on a 0 to 10 scale, as well as the intensity of their approval of the president and party preference on the generic ballot.

rica

ority Pro


### **FDA Prioritizes Lower-Cost Medication**






### **FDA Prioritizes Low-Cost Medication**

### NEW MAJORITY CROSSTABS






## **Joint Negotiation for Lower Prices for Patients**






## **Joint Negotiation for Lower Prices for Patients**

### NEW MAJORITY CROSSTABS






### **Modernize the FDA**





### **Modernize the FDA**

### NEW MAJORITY CROSSTABS




\*New Majority voters are determined through a screener survey of statements, asking respondents to rank their agreement on a 0 to 10 scale, as well as the intensity of their approval of the president and party preference on the generic ballot.

vica'

ority pro


## **Identify and Switch to Over-the-Counter Medication**





## **Identify and Switch to Over-the-Counter Medication**


### NEW MAJORITY CROSSTABS





## **Penalize Foreign Free Riding**

#### STANDARD CROSSTABS



29

40%

32

50%

60%

Gen X

0%

**Baby Boomer+** 

30

10%

30

20%

30%



**59** 

**59** 

**62** 

100%

22

24

90%

3

80%

70%


18

19

15


## **Penalize Foreign Free Riding**

### NEW MAJORITY CROSSTABS






## **Allow Pharmacists to Substitute Biosimilar Drugs**






## **Allow Pharmacists to Substitute Biosimilar Drugs**

### NEW MAJORITY CROSSTABS






## **Base Price of Drugs in US on European Prices**






## **Base Price of Drugs in US on European Prices**

### NEW MAJORITY CROSSTABS







New England	5%
Middle Atlantic	13%
East North Central	16%
West North Central	6%
South Atlantic	21%
East South Central	6%
West South Central	11%
Mountain	7%
Pacific	15%

%		18-29	15%
3%		30-40	17%
5%		41-55	25%
%		56-65	19%
۱%		66+	24%
%			
۱%		White	68%
%		Hispanic	13%
5%		Black	13%
	•	Asian	4%
		Other	2%

Male	47%
Female	53%
Democratic	36%
Republican	37%
Independent	27%
Less/4yr College	67%
Bachelor's/P.G	33%

### Methodology

Mclaughlin & Associates partnered with Gingrich360 to conduct a national survey for America's New Majority Project. This national survey was conducted among 2,000 registered voters between March 23-26, 2024.

All interviews were conducted online. Survey invitations were distributed randomly within predetermined geographic units. These units were structured to correlate with actual general election turnout.

The sample of 2,000 registered voters has an accuracy of +/- 2.2% at a 95% confidence interval. The numbers in this presentation have been rounded and may not equal 100%.

